BioSpace News Archive

Pharm Country

Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary

Applications For The Salix Gastrointestinal Health Scholars Program Will Be Accepted Beginning Nov. 1, 2019

October 30, 2019
·
4 min read
Business

NantHealth to Report 2019 Third-quarter Financial Results and Host Conference Call on Thursday, November 7

NantHealth, Inc., a next-generation, evidence-based, personalized healthcare company, announced that it will report financial results for its 2019 third quarter on Thursday, November 7, 2019, after market close.

October 30, 2019
·
1 min read
Business

Orchard Therapeutics to Webcast Conference Call of Third Quarter 2019 Financial Results

Orchard Therapeutics announced that the company will host a conference call and live webcast on Wednesday, November 6, 2019 at 4:30 p.m.

October 30, 2019
·
1 min read
Business

iCAD Reports Financial and Operating Results for the Third Quarter and Nine Months Ended September 30, 2019

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions reported its financial and operating results for the three and nine months ended September 30, 2019.

October 30, 2019
·
21 min read
Policy

EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of disease progression.

October 30, 2019
·
5 min read
Beactica Therapeutics Participates in Innovative Training Network on Targeted Protein Degradation

Beactica Therapeutics, the Swedish drug discovery company, announced its participation in a Marie Skłodowska-Curie Innovative Training Network called UbiMotif.

October 30, 2019
·
2 min read
Policy

European Commission Approves Astellas’ XOSPATA™ for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay

Invivoscribe, Inc. announced that the European Commission has approved the Astellas drug XOSPATA™ as a monotherapy for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with FLT3 mutations detected using Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay..

October 30, 2019
·
4 min read
Business

United Therapeutics Corporation Reports Third Quarter 2019 Financial Results

United Therapeutics Corporation announced its financial results for the quarter ended September 30, 2019.

October 30, 2019
·
14 min read
Business

Precision BioSciences to Report Third Quarter 2019 Financial Results and Present at Upcoming Investor Conferences in November

Precision BioSciences, Inc., a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced that it will publish financial results for the third quarter of 2019 and provide a corporate update on November 12, 2019.

October 30, 2019
·
1 min read
HTL invests in GMP manufacturing capacity to support fast growing market of Hyaluronic Acid Medical Applications

HTL, world leading supplier of Hyaluronic Acid and other biopolymer solutions, announces it is investing in a state-of-the-art production facility that will multiply its injectable grade sodium hyaluronate production capacity by 2.5 by 2021.

October 30, 2019
·
3 min read